Continuous Subcutaneous Insulin Infusion Market To Reach $1.14 Billion By 2030

Continuous Subcutaneous Insulin Infusion Market Growth & Trends

The global continuous subcutaneous insulin infusion market size is anticipated to reach USD 1.14 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 9.0% from 2025 to 2030. The key drivers of the market include increasing number of diabetes population coupled with technological advancement in the field of diabetes care.

According to International Diabetes Federation (IDF), the total number of diabetic population is expected to grow by 51.0% from 463.0 million in 2019 to 700.0 million in 2045. Rising health expenditure and growing awareness about preventive care is expected to boost market growth. According to the IDF, the estimated total global health expenditure to diabetes was USD 760.0 billion and is projected to grow to USD 845.0 billion by 2045. Furthermore, rising government initiatives to spread the awareness about diabetes is propelling the adoption of advanced diabetes management devices. Australian government launched Australian National Diabetes Strategy 2016 to 2020. The strategy aims to trace country’s national response to this epidemic and inform how existing limited healthcare can be better targeted across all level of government.

Increasing number of product launches and advent of artificial intelligence in the market is boosting the growth. Many startups are transforming CSII therapy. These companies are taking initiatives to lessen the burden of diabetes with help of AI technology. They are leveraging technological advancement to improve market solutions like integrated insulin pumps, non-invasive insulin delivery systems, and closed-loop artificial pancreases.

 Request a free sample copy or view report summary: Continuous Subcutaneous Insulin Infusion Market Report

Continuous Subcutaneous Insulin Infusion Market Report Highlights

• The patch pump segment is expected to grow at the fastest CAGR of 10.2% over the forecast period, owing to the increasing demand for convenient, customizable insulin delivery solutions that cater to people with higher insulin requirements, such as those with Type 2 diabetes.

• The diabetes type 1 segment held the largest market share of 82.1% in 2024, which can be attributed to the growing global prevalence of diabetes type 1, necessitating efficient and continuous insulin delivery solutions for better blood sugar management.

• The diabetes type 2 segment is expected to grow at the fastest CAGR of 10.0% over the forecast period.

• North America continuous subcutaneous insulin infusion market held the largest share of 39.2% in 2024, which can be attributed to the approval of advanced insulin pumps that feature meal detection technology and automatic insulin corrections, enhancing blood sugar control and making diabetes management more convenient for patients.

Continuous Subcutaneous Insulin Infusion Market Segmentation

Grand View Research has segmented the global continuous subcutaneous insulin infusion market report based on product, patient type, end-use, and region:

Continuous Subcutaneous Insulin Infusion Product Outlook (Revenue, USD Million, 2018 - 2030)

• Patch Pumps

  • Basal

  • Bolus

  • Basal and Bolus

• Tethered Pumps

  • Insulin Reservoir or Cartridges 

  • Insulin Set Insertion Devices

  • Battery

Continuous Subcutaneous Insulin Infusion Patient Type Outlook (Revenue, USD Million, 2018 - 2030)

• Diabetes Type 1

• Diabetes Type 2

Continuous Subcutaneous Insulin Infusion End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals & Clinics

• Homecare

• Laboratories

Continuous Subcutaneous Insulin Infusion Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Norway

  • Sweden

  • Denmark

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Continuous Subcutaneous Insulin Infusion Market

• Medtronic

• F. Hoffmann-La Roche Ltd

• ZEALAND PHARMA

• CeQur Simplicity

• Insulet Corporation

• YPSOMED

• B. Braun SE

• BD (Becton, Dickinson and Company)